Axiogenesis Cor.4U® Human
iPS Cell-Derived Cardiomyocytes
Axiogenesis AG has launched the Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocyte product line for use in testing the efficacy and safety of pharmaceutical therapies. Succeeding its flagship products, Cor.At® mouse ESC and iPSC derived cardiomyocytes (now marketed by Sigma Aldrich), Cor.4U® human iPS cell-derived cardiomyocytes are a result of the combined expertise of Shinya Yamanaka's Nobel Prize winning iPS cell technology with Axiogenesis' proprietary differentiation & production technology. These technologies enable the commercialization of pure in vitro differentiated human cardiomyocytes of premium quality, consistency and purity. Learn more about Cor.4U.
Cor.4U® iPS cell-derived cardiomyocytes have been validated in various applications including manual and automated Patch Clamp, Microelectrode Arrays (MEA), and xCELLigence Cardio. To request datasets and protocols,
As a pioneer of stem cell technology and the world leader in murine stem cell-derived products, Axiogenesis also offers pure in vitro differentiated smooth muscle cells (Smac.4M) and endothelial cells (Endo.4M), both available by Sigma Aldrich.
In addition to cell line products, Axiogenesis offers a unique service portfolio for in vitro toxicology and drug discovery. Axiogenesis provides assays in electrophysiology (Mel.Cor), cardiotoxicity (CardioEffect Screening) and embryotoxicity, as well as a proprietary in vitro disease model for cardiac hypertrophy.